The instrument company Gyros® AB (Gyros), based in Uppsala, Sweden, has appointed Erik Walldén as President and CEO. He will replace Lars Eric Utterman, who will join the board of Gyros after a successful year as acting CEO.

Erik Walldén will assume his new role on March 1, 2009. He has extensive experience within the biotech supply industry. In particular, his skills in the areas of international sales and strategic marketing will be key assets to Gyros during its current market-expansion phase.

Erik Walldén has, during his career, held several positions at executive level: most recently as CEO of Affibody Holding AB; and prior to that, as CEO of Biacore International AB and Pyrosequencing AB. Walldén is a member of the Industrial Supervisory Board of HealthInvest Partners AB, and a non-executive director of Exiqon A/S, Proxeon A/S and VisEn Medical Inc.

“I am very pleased with the recruitment of Erik as Gyros´ new CEO. He has in the past shown that he can successfully develop companies and create long term value for the owners as well as for the customers,” stated Per Carendi, chairman of Gyros and CEO of Scandinavian Life Science Ventures. “Gyros has now reached a stage where its technology is established in the market, and the first signs of market pull can be seen. The recruitment of Erik is also a proof of our strong belief in Gyros and the possibilities to further grow the business,” he concludes.